Cargando…

Randomised controlled trial of topical kanuka honey for the treatment of rosacea

OBJECTIVE: To investigate the efficacy of topical 90% medical-grade kanuka honey and 10% glycerine (Honevo) as a treatment for rosacea. DESIGN: Randomised controlled trial with blinded assessment of primary outcome variable. SETTING: Outpatient primary healthcare population from 5 New Zealand sites....

Descripción completa

Detalles Bibliográficos
Autores principales: Braithwaite, Irene, Hunt, Anna, Riley, Judith, Fingleton, James, Kocks, Janwillem, Corin, Andrew, Helm, Colin, Sheahan, Davitt, Tofield, Christopher, Montgomery, Barney, Holliday, Mark, Weatherall, Mark, Beasley, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480029/
https://www.ncbi.nlm.nih.gov/pubmed/26109117
http://dx.doi.org/10.1136/bmjopen-2015-007651
_version_ 1782378110550802432
author Braithwaite, Irene
Hunt, Anna
Riley, Judith
Fingleton, James
Kocks, Janwillem
Corin, Andrew
Helm, Colin
Sheahan, Davitt
Tofield, Christopher
Montgomery, Barney
Holliday, Mark
Weatherall, Mark
Beasley, Richard
author_facet Braithwaite, Irene
Hunt, Anna
Riley, Judith
Fingleton, James
Kocks, Janwillem
Corin, Andrew
Helm, Colin
Sheahan, Davitt
Tofield, Christopher
Montgomery, Barney
Holliday, Mark
Weatherall, Mark
Beasley, Richard
author_sort Braithwaite, Irene
collection PubMed
description OBJECTIVE: To investigate the efficacy of topical 90% medical-grade kanuka honey and 10% glycerine (Honevo) as a treatment for rosacea. DESIGN: Randomised controlled trial with blinded assessment of primary outcome variable. SETTING: Outpatient primary healthcare population from 5 New Zealand sites. PARTICIPANTS: 138 adults aged ≥16, with a diagnosis of rosacea, and a baseline blinded Investigator Global Assessment of Rosacea Severity Score (IGA-RSS) of ≥2. 69 participants were randomised to each treatment arm. 1 participant was excluded from the Honevo group, and 7 and 15 participants withdrew from the Honevo and control groups, respectively. INTERVENTIONS: Participants were randomly allocated 1:1 to Honevo or control cream (Cetomacrogol), applied twice daily for 8 weeks. MAIN OUTCOME MEASURES: The primary outcome measure was the proportion of participants who had a ≥2 improvement in the 7-point IGA-RSS at week 8 compared to baseline. Secondary outcomes included change in IGA-RSS and subject-rated visual analogue score of change in severity (VAS-CS) on a 100 mm scale (0 mm ‘much worse’, 100 mm ‘much improved’) at weeks 2 and 8. RESULTS: 24/68 (34.3%) in the Honevo group and 12/69 (17.4%) in the control group had a ≥2 improvement in IGA-RSS at week 8 compared to baseline (relative risk 2.03; 95% CI 1.11 to 3.72, p=0.020). The change in IGA-RSS for Honevo compared to control at week 2 minus baseline was −1 (Hodges-Lehman estimate, 95% CI −1 to 0, p=0.03), and at week 8 minus baseline was −1 (Hodges-Lehman estimate, 95% CI −1 to 0, p=0.005). The VAS-CS at week 2 was 9.1 (95% CI 3.5 to 14.7), p=0.002, and at week 8 was 12.3 (95% CI 5.7 to 18.9)¸ p<0.001 for Honevo compared to control. CONCLUSIONS: Honevo is an effective treatment for rosacea. TRIAL REGISTRATION NUMBER: This trial was registered in the Australian and New Zealand Clinical Trials Registry ACTRN12614000004662.
format Online
Article
Text
id pubmed-4480029
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44800292015-07-02 Randomised controlled trial of topical kanuka honey for the treatment of rosacea Braithwaite, Irene Hunt, Anna Riley, Judith Fingleton, James Kocks, Janwillem Corin, Andrew Helm, Colin Sheahan, Davitt Tofield, Christopher Montgomery, Barney Holliday, Mark Weatherall, Mark Beasley, Richard BMJ Open Complementary Medicine OBJECTIVE: To investigate the efficacy of topical 90% medical-grade kanuka honey and 10% glycerine (Honevo) as a treatment for rosacea. DESIGN: Randomised controlled trial with blinded assessment of primary outcome variable. SETTING: Outpatient primary healthcare population from 5 New Zealand sites. PARTICIPANTS: 138 adults aged ≥16, with a diagnosis of rosacea, and a baseline blinded Investigator Global Assessment of Rosacea Severity Score (IGA-RSS) of ≥2. 69 participants were randomised to each treatment arm. 1 participant was excluded from the Honevo group, and 7 and 15 participants withdrew from the Honevo and control groups, respectively. INTERVENTIONS: Participants were randomly allocated 1:1 to Honevo or control cream (Cetomacrogol), applied twice daily for 8 weeks. MAIN OUTCOME MEASURES: The primary outcome measure was the proportion of participants who had a ≥2 improvement in the 7-point IGA-RSS at week 8 compared to baseline. Secondary outcomes included change in IGA-RSS and subject-rated visual analogue score of change in severity (VAS-CS) on a 100 mm scale (0 mm ‘much worse’, 100 mm ‘much improved’) at weeks 2 and 8. RESULTS: 24/68 (34.3%) in the Honevo group and 12/69 (17.4%) in the control group had a ≥2 improvement in IGA-RSS at week 8 compared to baseline (relative risk 2.03; 95% CI 1.11 to 3.72, p=0.020). The change in IGA-RSS for Honevo compared to control at week 2 minus baseline was −1 (Hodges-Lehman estimate, 95% CI −1 to 0, p=0.03), and at week 8 minus baseline was −1 (Hodges-Lehman estimate, 95% CI −1 to 0, p=0.005). The VAS-CS at week 2 was 9.1 (95% CI 3.5 to 14.7), p=0.002, and at week 8 was 12.3 (95% CI 5.7 to 18.9)¸ p<0.001 for Honevo compared to control. CONCLUSIONS: Honevo is an effective treatment for rosacea. TRIAL REGISTRATION NUMBER: This trial was registered in the Australian and New Zealand Clinical Trials Registry ACTRN12614000004662. BMJ Publishing Group 2015-06-24 /pmc/articles/PMC4480029/ /pubmed/26109117 http://dx.doi.org/10.1136/bmjopen-2015-007651 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Complementary Medicine
Braithwaite, Irene
Hunt, Anna
Riley, Judith
Fingleton, James
Kocks, Janwillem
Corin, Andrew
Helm, Colin
Sheahan, Davitt
Tofield, Christopher
Montgomery, Barney
Holliday, Mark
Weatherall, Mark
Beasley, Richard
Randomised controlled trial of topical kanuka honey for the treatment of rosacea
title Randomised controlled trial of topical kanuka honey for the treatment of rosacea
title_full Randomised controlled trial of topical kanuka honey for the treatment of rosacea
title_fullStr Randomised controlled trial of topical kanuka honey for the treatment of rosacea
title_full_unstemmed Randomised controlled trial of topical kanuka honey for the treatment of rosacea
title_short Randomised controlled trial of topical kanuka honey for the treatment of rosacea
title_sort randomised controlled trial of topical kanuka honey for the treatment of rosacea
topic Complementary Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480029/
https://www.ncbi.nlm.nih.gov/pubmed/26109117
http://dx.doi.org/10.1136/bmjopen-2015-007651
work_keys_str_mv AT braithwaiteirene randomisedcontrolledtrialoftopicalkanukahoneyforthetreatmentofrosacea
AT huntanna randomisedcontrolledtrialoftopicalkanukahoneyforthetreatmentofrosacea
AT rileyjudith randomisedcontrolledtrialoftopicalkanukahoneyforthetreatmentofrosacea
AT fingletonjames randomisedcontrolledtrialoftopicalkanukahoneyforthetreatmentofrosacea
AT kocksjanwillem randomisedcontrolledtrialoftopicalkanukahoneyforthetreatmentofrosacea
AT corinandrew randomisedcontrolledtrialoftopicalkanukahoneyforthetreatmentofrosacea
AT helmcolin randomisedcontrolledtrialoftopicalkanukahoneyforthetreatmentofrosacea
AT sheahandavitt randomisedcontrolledtrialoftopicalkanukahoneyforthetreatmentofrosacea
AT tofieldchristopher randomisedcontrolledtrialoftopicalkanukahoneyforthetreatmentofrosacea
AT montgomerybarney randomisedcontrolledtrialoftopicalkanukahoneyforthetreatmentofrosacea
AT hollidaymark randomisedcontrolledtrialoftopicalkanukahoneyforthetreatmentofrosacea
AT weatherallmark randomisedcontrolledtrialoftopicalkanukahoneyforthetreatmentofrosacea
AT beasleyrichard randomisedcontrolledtrialoftopicalkanukahoneyforthetreatmentofrosacea